Sarepta Jumps On Hopes For Muscular Dystrophy Drug

Sarepta Therapeutics ( SRPT ) has had a wild ride this week, losing nearly 20% after an FDA vote on Tuesday that denied accelerated approval to its Duchenne muscular dystrophy drug, eteplirsen. Yet the stock closed up 13.5% to $13.80 Thursday. Today, TheStreet.com argued that hope isn’t lost for a speedy FDA approval , despite the negative vote earlier this week, and that sentiment was echoed by Jim Cramer , who talked up drug’s safety profile . Read More »